share_log

Institutional Investors May Adopt Severe Steps After Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Latest 12% Drop Adds to a Year Losses

Institutional Investors May Adopt Severe Steps After Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Latest 12% Drop Adds to a Year Losses

继Allogene Therapeutics, Inc.之后,机构投资者可能会采取严厉措施s(纳斯达克股票代码:ALLO)最近12%的跌幅增加了年度亏损
Simply Wall St ·  05/23 13:46

Key Insights

关键见解

  • Significantly high institutional ownership implies Allogene Therapeutics' stock price is sensitive to their trading actions
  • A total of 8 investors have a majority stake in the company with 51% ownership
  • Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
  • 高机构所有权意味着Allogene Therapeutics的股价对其交易行为很敏感
  • 共有8名投资者持有该公司的多数股权,所有权为51%
  • 分析师的预测以及所有权数据可以使人们对企业前景有深刻的了解

A look at the shareholders of Allogene Therapeutics, Inc. (NASDAQ:ALLO) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 55% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

看看Allogene Therapeutics, Inc.(纳斯达克股票代码:ALLO)的股东可以告诉我们哪个集团最强大。而持有最大份额的集团是拥有55%所有权的机构。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。

As a result, institutional investors endured the highest losses last week after market cap fell by US$73m. The recent loss, which adds to a one-year loss of 51% for stockholders, may not sit well with this group of investors. Institutions or "liquidity providers" control large sums of money and therefore, these types of investors usually have a lot of influence over stock price movements. As a result, if the downtrend continues, institutions may face pressures to sell Allogene Therapeutics, which might have negative implications on individual investors.

结果,在市值下降7300万美元之后,机构投资者上周遭受了最大的损失。最近的亏损加上股东一年的亏损51%,可能不适合这群投资者。机构或 “流动性提供者” 控制着大量资金,因此,这些类型的投资者通常对股价走势有很大的影响力。因此,如果下跌趋势持续下去,机构可能会面临出售Allogene Therapeutics的压力,这可能会对个人投资者产生负面影响。

In the chart below, we zoom in on the different ownership groups of Allogene Therapeutics.

在下图中,我们放大了Allogene Therapeutics的不同所有权群体。

ownership-breakdown
NasdaqGS:ALLO Ownership Breakdown May 23rd 2024
纳斯达克GS:ALLO所有权明细 2024年5月23日

What Does The Institutional Ownership Tell Us About Allogene Therapeutics?

关于异基因疗法,机构所有权告诉我们什么?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见指数的回报进行比较。因此,他们通常会考虑收购相关基准指数中包含的大型公司。

Allogene Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Allogene Therapeutics' earnings history below. Of course, the future is what really matters.

Allogene Therapeutics已经在股票登记处设立了机构。事实上,他们拥有该公司可观的股份。这可能表明该公司在投资界具有一定程度的信誉。但是,最好谨慎行事,不要依赖机构投资者所谓的验证。他们也是,有时候会弄错。如果多家机构同时改变对股票的看法,你可能会看到股价快速下跌。因此,值得在下面查看Allogene Therapeutics的收益记录。当然,未来才是真正重要的。

earnings-and-revenue-growth
NasdaqGS:ALLO Earnings and Revenue Growth May 23rd 2024
纳斯达克GS:ALLO收益和收入增长 2024年5月23日

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. We note that hedge funds don't have a meaningful investment in Allogene Therapeutics. FMR LLC is currently the largest shareholder, with 12% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 11% and 9.0%, of the shares outstanding, respectively. Furthermore, CEO David Chang is the owner of 3.7% of the company's shares.

机构投资者拥有公司50%以上的股份,因此加在一起可能会对董事会的决策产生重大影响。我们注意到,对冲基金没有对Allogene Therapeutics进行有意义的投资。FMR LLC目前是最大股东,已发行股份的12%。同时,第二和第三大股东分别持有已发行股份的11%和9.0%。此外,首席执行官张大卫持有公司3.7%的股份。

We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

我们还观察到,前8名股东占股票登记册的一半以上,少数规模较小的股东可以在一定程度上平衡大股东的利益。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。有很多分析师在报道该股,因此可能也值得一看他们的预测。

Insider Ownership Of Allogene Therapeutics

异基因疗法的内部所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层对董事会负责,后者应代表股东的利益。值得注意的是,有时高层管理人员自己也是董事会成员。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多数人认为内部所有权是积极的,因为这可能表明董事会与其他股东关系良好。但是,在某些情况下,过多的权力集中在该群体中。

We can see that insiders own shares in Allogene Therapeutics, Inc.. In their own names, insiders own US$32m worth of stock in the US$555m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

我们可以看到内部人士拥有Allogene Therapeutics, Inc.的股份。内部人士以自己的名义拥有这家价值5.55亿美元的公司价值3200万美元的股票。很高兴看到内部人士进行一些投资,但可能值得检查一下这些内部人士是否在买入。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 20% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

包括散户投资者在内的公众拥有该公司20%的股份,因此不容忽视。尽管这种所有权规模可能不足以影响对他们有利的政策决定,但它们仍然可以对公司政策产生集体影响。

Private Equity Ownership

私募股权所有权

Private equity firms hold a 9.0% stake in Allogene Therapeutics. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

私募股权公司持有Allogene Therapeutics9.0%的股份。这表明他们可以在关键政策决策中发挥影响力。有些人可能会喜欢这样,因为私募股权有时是追究管理层责任的激进分子。但是其他时候,私募股权在公司上市后正在售罄。

Public Company Ownership

上市公司所有权

It appears to us that public companies own 11% of Allogene Therapeutics. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

在我们看来,上市公司拥有Allogene Therapeutics11%的股份。很难肯定地说,但这表明它们将商业利益交织在一起。这可能是一个战略利害关系,因此值得关注这个领域的所有权变动。

Next Steps:

后续步骤:

It's always worth thinking about the different groups who own shares in a company. But to understand Allogene Therapeutics better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for Allogene Therapeutics (of which 1 is a bit concerning!) you should know about.

拥有公司股份的不同群体总是值得考虑的。但是,为了更好地了解异基因疗法,我们需要考虑许多其他因素。比如风险。每家公司都有它们,我们发现了 Allogene Therapeutics 的 3 个警告信号(其中 1 个有点令人担忧!)你应该知道。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

归根结底,未来是最重要的。您可以访问这份关于公司分析师预测的免费报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发